192 patients were admitted to the cardiac ICU with cardiogenic shock and were randomized to receive either milrinone or dobutamine. The two groups were not different in baseline characteristics. Composite primary outcome or secondary outcome were not different among the two groups concluding that no benefit of milrinone over dobutamine. However, it is a single center study and only in-hospital outcome measures were evaluated.
Amazing to have such a small cohort getting published in a respected Journal @nejm